

# Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

## Rabbit anti-Phospho RNA Polymerase II (S5) Antibody, Affinity Purified

RRID:AB\_2268550

Type: Antibody

### Proper Citation

Bethyl Cat# A300-655A, RRID:AB\_2268550

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2268550](http://antibodyregistry.org/AB_2268550)

**Proper Citation:** Bethyl Cat# A300-655A, RRID:AB\_2268550

**Target Antigen:** RNA Polymerase II pS5

**Host Organism:** rabbit

**Clonality:** unknown

**Comments:** Discontinued: 2016; Original manufacturer of this product; IHC validation was performed using Immunohistochemistry Accessory Kit (Cat. # IHC-101). Applications: WB,IHC Paraffin,IF Dilution: WB - 1:2,500 - 1:20,000 / IHC - 1:200 to 1:1,000. Epitope retrieval with citrate buffer pH6.0 is recommended for FFPE tissue sections. / IF - 1:100 to 1:500.

**Antibody Name:** Rabbit anti-Phospho RNA Polymerase II (S5) Antibody, Affinity Purified

**Description:** This unknown targets RNA Polymerase II pS5

**Target Organism:** mouse, human

**Antibody ID:** AB\_2268550

**Vendor:** Bethyl

**Catalog Number:** A300-655A

**Record Creation Time:** 20250819T230923+0000

**Record Last Update:** 20250820T042740+0000

### Ratings and Alerts

No rating or validation information has been found for Rabbit anti-Phospho RNA Polymerase II (S5) Antibody, Affinity Purified.

**Warning:** Discontinued: 2016

Discontinued: 2016; Original manufacturer of this product; IHC validation was performed using Immunohistochemistry Accessory Kit (Cat. # IHC-101). Applications: WB,IHC Paraffin,IF Dilution: WB - 1:2,500 - 1:20,000 / IHC - 1:200 to 1:1,000. Epitope retrieval with citrate buffer pH6.0 is recommended for FFPE tissue sections. / IF - 1:100 to 1:500.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Shan W, et al. (2020) Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment. Cell reports, 32(2), 107884.